Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial.

Journal of Diabetes Investigation
Atsushi TanakaKoichi Node

Abstract

Recent clinical trials on sodium-glucose cotransporter 2 inhibitors showed improved outcomes in patients with type 2 diabetes at a high risk of cardiovascular events. However, the underlying effects on endothelial function remain unclear. The effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized (EMBLEM) trial in patients with type 2 diabetes and cardiovascular disease showed empagliflozin treatment for 24 weeks had no effect on peripheral endothelial function measured by reactive hyperemia peripheral arterial tonometry. This post-hoc analysis of the EMBLEM trial included a detailed evaluation of the effects of empagliflozin on peripheral endothelial function in order to elucidate the clinical characteristics of responders or non-responders to treatment. Of the 47 patients randomized into the empagliflozin group, 21 (44.7%) showed an increase in the reactive hyperemia index (RHI) after 24 weeks of intervention, with no apparent difference in the clinical characteristics between patients whose RHI either increased (at least >0) or did not increase. There was also no obvious difference between the treatment groups in the proportion of...Continue Reading

References

Jan 14, 1999·The New England Journal of Medicine·R Ross
Jul 10, 2003·American Heart Journal·Jeffrey T KuvinJames E Udelson
Oct 3, 2003·Journal of the American College of Cardiology·Michael E WidlanskyJoseph A Vita
Apr 29, 2004·JAMA : the Journal of the American Medical Association·James B MeigsJoAnn E Manson
Dec 8, 2004·Journal of the American College of Cardiology·Piero O BonettiAmir Lerman
Oct 21, 2006·Journal of Hypertension·Teruo Inoue, Koichi Node
Jan 24, 2009·Journal of the American College of Cardiology·Yoshinobu KittaKiyotaka Kugiyama
Sep 4, 2010·Journal of the American College of Cardiology·Barry A BorlaugMargaret M Redfield
May 4, 2013·European Heart Journal·Francesco PaneniFrancesco Cosentino
Sep 10, 2013·European Heart Journal·Enrique GutiérrezFrancisco Fernández-Avilés
Jan 16, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Silvio E InzucchiOdd Erik Johansen
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jan 4, 2017·Journal of cardiology·Atsushi Tanaka, Koichi Node
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Aug 12, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yoshiaki KubotaWataru Shimizu
Oct 26, 2018·Hypertension·Atsushi TanakaUNKNOWN Physiological Diagnosis Criteria for Vascular Failure Committee
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Apr 30, 2020·ESC Heart Failure·Atsushi TanakaUNKNOWN CANDLE Trial Investigators

❮ Previous
Next ❯

Citations

Aug 12, 2021·Heart Failure Reviews·Michele CorrealeNatale Daniele Brunetti
Sep 15, 2021·Cardiovascular Drugs and Therapy·Michele CorrealeNatale Daniele Brunetti

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass

Software Mentioned

RH
PAT
SAS
EMBLEM

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.